# A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

> **NCT02356991** · PHASE2 · SUSPENDED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 137 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Famitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02356991
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2014-12
- **Primary completion:** 2020-06
- **Final completion:** 2020-06
- **Target enrollment:** 137 (ACTUAL)
- **Why stopped:** sponsor decides to suspend this trial
- **Last updated:** 2019-11-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02356991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02356991, "A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02356991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*